Comerica Bank Sells 14,195 Shares of Biogen Inc. $BIIB

Key Points

• Comerica Bank cut its stake in Biogen by 42.2%, selling 14,195 shares and leaving it with 19,475 shares worth about $3.43 million.
• Biogen beat Q1 estimates (EPS $3.57 vs $2.95; revenue $2.48B vs $2.29B) and set FY2026 guidance of 14.25–15.25 EPS, prompting mixed analyst moves but a consensus target of $214.23.
• The announced Apellis transaction will create a ~$120–$130M other‑income headwind in 2026 (with non‑GAAP EPS accretion expected in 2027), while institutional investors now own roughly 87.9% of the stock and several large funds increased their positions.

Comerica Bank cut its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 42.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 19,475 shares of the biotechnology company's stock after selling 14,195 shares during the quarter. Comerica Bank's holdings in Biogen were worth $3,427,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BIIB. Nippon Life Global Investors Americas Inc. acquired a new stake in shares of Biogen in the fourth quarter valued at $4,662,000. Aprio Wealth Management LLC acquired a new stake in shares of Biogen in the fourth quarter valued at $343,000. Pictet Asset Management Holding SA increased its stake in shares of Biogen by 22.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 947,494 shares of the biotechnology company's stock valued at $166,900,000 after buying an additional 176,639 shares in the last quarter. Sanctuary Advisors LLC increased its stake in shares of Biogen by 36.2% in the fourth quarter. Sanctuary Advisors LLC now owns 5,172 shares of the biotechnology company's stock valued at $910,000 after buying an additional 1,375 shares in the last quarter. Finally, AEGON ASSET MANAGEMENT UK Plc increased its stake in shares of Biogen by 33.0% in the fourth quarter. AEGON ASSET MANAGEMENT UK Plc now owns 260,162 shares of the biotechnology company's stock valued at $45,786,000 after buying an additional 64,527 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q1 beat driven by growth from newer drugs (Leqembi, Skyclarys) and upbeat revenue/profit metrics that underpin optimism about Biogen’s growth portfolio. Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
• Positive Sentiment: RBC raised its price target to $222 and maintained an Outperform rating, signaling strong analyst conviction and upside potential for BIIB. RBC raises PT to $222
• Positive Sentiment: H.C. Wainwright reiterated a Buy and lifted its PT to $237, citing reduced risk on BIIB080 (Alzheimer’s) — a bullish signal for upside from pipeline progress. H.C. Wainwright reiterates Buy, PT $237
• Positive Sentiment: TD Cowen initiated / affirmed a Buy with a $215 price target, citing strong Q1, pipeline progress and the Apellis deal as supportive factors. TD Cowen Buy, PT $215
• Positive Sentiment: Rothschild & Co Redburn nudged its PT up to $190 (small upside), reflecting modestly improved near-term views. Rothschild raises PT to $190
• Neutral Sentiment: BMO kept a Market Perform/Hold rating with an unchanged $196 target, signaling that some analysts see constrained near-term growth despite the beat. BMO maintains Hold, PT $196
• Neutral Sentiment: Several analyst notes and commentary highlight mixed takeaways: firms generally raised forecasts after the Q1 beat but some also trimmed FY2026 EPS expectations, producing varied buy/hold calls. Analysts boost forecasts after Q1
• Negative Sentiment: Biogen disclosed the Apellis transaction will create a ~$120M–$130M other‑income headwind in 2026 (non‑GAAP EPS accretion expected in 2027), creating a near‑term earnings drag that pressured sentiment. Apellis deal impact
• Negative Sentiment: Sanford C. Bernstein trimmed its PT slightly from $201 to $200 — a modest negative signal that may contribute to profit-taking amid mixed analyst reactions. Bernstein trims PT to $200

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Oppenheimer raised their target price on Biogen from $250.00 to $275.00 and gave the company an "outperform" rating in a research note on Wednesday, April 1st. Argus upgraded Biogen to a "hold" rating in a research note on Thursday, April 9th. Wolfe Research set a $231.00 target price on Biogen in a research note on Monday, February 9th. JPMorgan Chase & Co. raised their target price on Biogen from $175.00 to $185.00 and gave the company a "neutral" rating in a research note on Thursday, April 23rd. Finally, Wedbush raised their target price on Biogen from $191.00 to $196.00 and gave the company a "neutral" rating in a research note on Thursday. Thirteen investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $214.23.

Insider Transactions at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the firm's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is currently owned by corporate insiders.

Biogen Price Performance

Biogen stock opened at $187.06 on Monday. The business's 50-day simple moving average is $184.52 and its 200 day simple moving average is $176.50. The stock has a market cap of $27.62 billion, a price-to-earnings ratio of 20.07, a P/E/G ratio of 1.53 and a beta of 0.19. Biogen Inc. has a 12-month low of $115.25 and a 12-month high of $202.41. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion for the quarter, compared to analysts' expectations of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm's quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the business earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, research analysts anticipate that Biogen Inc. will post 15.24 earnings per share for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.